Browsing by Author "Cicin, I."
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvilli, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item Multicenter real life expeMulticenter real life experience of biological agents in patients with metastatic colorectal cancerrience of biological agents in patients with metastatic colorectal cancer(2020) Demirci, U.; Erturk, I.; Arslan, C.; Bilici, A.; Cevik, D.; Cicin, I.; Dane, F.; Dolek, B.; Kaplan, M.; Karadurmus, N.; Kose, F.; Sendur, M.; Urun, Y.; Kilickap, S.Item Pertuzumab, Trastuzumab and Taxane Combination for Visceral Organ Metastatic Patients: Real Life Practice Results(2018) Esin, E.; Oksuzoglu, O. B. Cakmak; Bilici, A.; Cicin, I.; Aksoy, S.; Alacacioglu, A.; Kaplan, M. A.; Cabuk, D.; Sumbul, A. T.; Paydas, S.; Sakin, A.; Er, O.; Korkmaz, T.; Yildirim, N.; Artac, M.; Harputluoglu, H.; Yumuk, P. F.; Basaran, G.; Uluc, B. Oyan; Demirci, U.; 0000-0002-5573-906X; D-4793-2014Item Three Years Survival Outcome And Continued Cemiplimab (CEMI) Beyond Progression With The Addition Of Chemotherapy (Chemo) For Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): The EMPOWER-Lung 1 Trial(2022) Ozguroglu, M.; Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Nechaeva, M.; Schenker, M.; Cicin, I.; Ho, G. F.; Kulyaba, Y.; Dvorkin, M.; Zyuhal, K.; Scheusan, R. I.; Li, S.; Pouliot, J-F.; Seebach, F.; Lowy, I.; Gullo, G.; Rietschel, P.